據報美國官員完成審查藥明生物(02269.HK)旗下無錫公司
近日傳出藥明生物(02269.HK)兩間子公司無錫藥明生物及上海藥明生物可能接近從美國商務部的未經核實名單中除名。據內媒報道指,中國商務部上周允許一名美國出口管制官員審查無錫市至少一家公司,預期官員未來數周或改到安徽繼續審查工作。
內媒並引述藥明生物負責人指,旗下無錫公司接近完成審查,一切順利;至於同系的上海藥明生物,有傳目前仍在等待審查,由於兩家公司為不同的法律實體,相信無錫公司可單獨獲解除制裁,不受上海公司審查進度影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.